Spero Therapeutics, Inc. (SPRO) intrinsic value & 10-year financials
Spero Therapeutics, Inc. (SPRO) has a Graham intrinsic value of $4.98 per share. At $1.10 on Oct 17, 2026, the stock trades 78% below that value. Over the last 10 fiscal years revenue grew 49.6% a year to $12.6M, with an average return on invested capital of -56.2%.
- Graham intrinsic value
- $4.98
- Share price (Oct 17, 2026)
- $1.10
- Price vs Graham value
- 78% below
- Market cap
- $64.9M
- Revenue (FY2025)
- $12.6M
- Revenue growth (10-yr CAGR)
- 49.6%
- ROIC (10-yr avg)
- -56.2%
- Free cash flow (FY2025)
- —
SPRO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $12.6M | $8.6M | $0.15 | — | 50.2% | 79.2% |
| FY2024 | $371.0K | -$68.6M | -$1.27 | — | -19773.9% | -486.3% |
| FY2023 | $933.0K | $22.8M | $0.43 | — | 2302.4% | 625.1% |
| FY2022 | $48.6M | -$46.4M | -$1.23 | — | -86.9% | 181.3% |
| FY2021 | $3.1M | -$89.8M | -$2.91 | — | -2865.5% | -497.0% |
| FY2020 | $258.0K | -$78.3M | — | -$86.0M | -30664.0% | -153.3% |
| FY2019 | $4.7M | -$60.9M | — | -$50.3M | -1333.1% | -127.8% |
| FY2018 | $4.0M | -$41.7M | — | -$42.1M | -1079.3% | -42.8% |
| FY2017 | $2.0M | -$38.7M | — | -$39.1M | -2108.6% | -213.1% |
| FY2016 | $335.0K | -$25.5M | — | -$29.8M | -9916.7% | 73.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Spero Therapeutics, Inc. is a consistent compounder, expanding top-line revenue at 49.6% annually over the past decade.
Spero Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -2.4% ROIC.
Spero Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Spero Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $4.98 per share.